KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $8.5 billion.

  • Eli Lilly's Other Accumulated Expenses rose 3220.26% to $8.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $8.5 billion, marking a year-over-year increase of 3220.26%. This contributed to the annual value of $8.5 billion for FY2025, which is 3220.26% up from last year.
  • As of Q4 2025, Eli Lilly's Other Accumulated Expenses stood at $8.5 billion, which was up 3220.26% from $5.2 billion recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Other Accumulated Expenses ranged from a high of $8.5 billion in Q4 2025 and a low of $2.0 billion during Q3 2022
  • For the 5-year period, Eli Lilly's Other Accumulated Expenses averaged around $3.7 billion, with its median value being $2.9 billion (2021).
  • As far as peak fluctuations go, Eli Lilly's Other Accumulated Expenses tumbled by 2367.33% in 2022, and later surged by 11583.89% in 2024.
  • Eli Lilly's Other Accumulated Expenses (Quarter) stood at $3.0 billion in 2021, then dropped by 6.01% to $2.8 billion in 2022, then increased by 15.32% to $3.3 billion in 2023, then soared by 94.95% to $6.4 billion in 2024, then soared by 32.2% to $8.5 billion in 2025.
  • Its Other Accumulated Expenses was $8.5 billion in Q4 2025, compared to $5.2 billion in Q3 2025 and $5.1 billion in Q2 2025.